Phenotypes associated with this allele

• Allele Symbol: Tg(Acta2-cre/ERT2)#Pcn
• Allele Name: transgene insertion, Pierre Chambon
• Allele ID: MGI:5305721
• Summary: 2 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
cn1	Tg(Acta2-cre/ERT2)#Pcn/0 Tgfbr2^tm1Karl/Tgfbr2^tm1Karl Tg(H2-K-Fosl2,-EGFP)13Wag/0	B6.Cg-Tgfbr2^tm1Karl Tg(Acta2-cre/ERT2)#Pcn Tg(H2-K-Fosl2,-EGFP)13Wag	MGI:5927438
cn2	Nr3c2^tm1.1Ics/Nr3c2^tm1.1Ics Tg(Acta2-cre/ERT2)#Pcn/0	involves: 129S2/SvPas * FVB/N	MGI:5475012

Genotype
MGI:5927438

cn1

• Allelic Composition: Tg(Acta2-cre/ERT2)#Pcn/0; Tgfbr2^tm1Karl/Tgfbr2^tm1Karl; Tg(H2-K-Fosl2,-EGFP)13Wag/0
• Genetic Background: B6.Cg-Tgfbr2^tm1Karl Tg(Acta2-cre/ERT2)#Pcn Tg(H2-K-Fosl2,-EGFP)13Wag

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

respiratory system

lung inflammation ( J:238723 )

• mice treated with tamoxifen show similar lung inflammation as single Tg(H2-K-Fosl2,EGFP)13Wag mice

pulmonary fibrosis ( J:238723 )

• mice treated with tamoxifen show similar pulmonary fibrosis as single Tg(H2-K-Fosl2,EGFP)13Wag mice

immune system

lung inflammation ( J:238723 )

• mice treated with tamoxifen show similar lung inflammation as single Tg(H2-K-Fosl2,EGFP)13Wag mice

cardiovascular system

cardiovascular system phenotype ( J:238723 )

N • mice treated with tamoxifen show diminished expansion of the smooth muscle cell area in pulmonary arteries and reduced proliferation of pulmonary artery smooth muscle cells that is seen in single Tg(H2-K-Fosl2,EGFP)13Wag mice

Genotype
MGI:5475012

cn2

• Allelic Composition: Nr3c2^tm1.1Ics/Nr3c2^tm1.1Ics; Tg(Acta2-cre/ERT2)#Pcn/0
• Genetic Background: involves: 129S2/SvPas * FVB/N

cardiovascular system

cardiovascular system phenotype ( J:193438 )

N • tamoxifen-treated mice exhibit normal vascular structure and blood pressure response to altered sodium content diets

decreased heart weight ( J:193438 )

• aged tamoxifen-treated mice do not develop cardiac hypertrophy unlike control mice

decreased systemic arterial systolic blood pressure ( J:193438 )

• in adult and aged tamoxifen-treated mice in response to Ang II

• however, diurnal blood pressure variation is normal

• in tamoxifen-treated mice by 7 months of age

abnormal vasoconstriction ( J:193438 )

• aged tamoxifen-treated mice fail to exhibit an increase in contraction response to KCL or U46619 (thromboxane receptor agonist) unlike control mice

• however, the age-dependent increase in contraction response to phenylephrine is preserved

decreased vasoconstriction ( J:193438 )

• in tamoxifen-treated mice in response to phenylephrine

• in adult tamoxifen-treated mice in response to acetylcholine

• in aged tamoxifen-treated mice in response to BayK8644 (L-type calcium channel agonist)

• in adult and aged tamoxifen-treated mice in response to Ang II

increased vasoconstriction ( J:193438 )

• in aged tamoxifen-treated mice in response to sodium nitroprusside

abnormal vasodilation ( J:193438 )

• aged tamoxifen-treated mice exhibit a modest decrease in endothelial cell-independent vasodilation compared with control mice

increased vasodilation ( J:193438 )

• endothelial-dependent tamoxifen-treated mice

renal/urinary system

renal/urinary system phenotype ( J:193438 )

N • tamoxifen-treated mice exhibit intact renal function

cellular

abnormal redox activity ( J:193438 )

• adult tamoxifen-treated mice exhibit attenuated AngII-stimulated reactive oxygen species production compared with control mice

• aged tamoxifen-treated mice exhibit attenuated reactive oxygen species production prior to and after AngII-stimulation compared with control mice

muscle

abnormal vasoconstriction ( J:193438 )

• aged tamoxifen-treated mice fail to exhibit an increase in contraction response to KCL or U46619 (thromboxane receptor agonist) unlike control mice

• however, the age-dependent increase in contraction response to phenylephrine is preserved

decreased vasoconstriction ( J:193438 )

• in tamoxifen-treated mice in response to phenylephrine

• in adult tamoxifen-treated mice in response to acetylcholine

• in aged tamoxifen-treated mice in response to BayK8644 (L-type calcium channel agonist)

• in adult and aged tamoxifen-treated mice in response to Ang II

increased vasoconstriction ( J:193438 )

• in aged tamoxifen-treated mice in response to sodium nitroprusside

abnormal vasodilation ( J:193438 )

• aged tamoxifen-treated mice exhibit a modest decrease in endothelial cell-independent vasodilation compared with control mice

increased vasodilation ( J:193438 )

• endothelial-dependent tamoxifen-treated mice

abnormal muscle tone ( J:193438 )

• aged tamoxifen-treated mice develop less spontaneous myogenic tone compared with control mice